$42.00
(Market cap
$20,209 Mln
Revenue (TTM)
$2,459 Mln
P/E Ratio
--
P/B Ratio
7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-882 Mln
-
ROE
-0.2 %
-
ROCE
-19.7 %
-
Industry P/E
--
-
EV/EBITDA
-11.9
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
97,675,800
10 Years Aggregate
CFO
$-6,659.54 Mln
EBITDA
$-7,912.40 Mln
Net Profit
$-7,811.45 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
| 22.7 | 24.6 | 4.4 | 40.0 | 2.1 | 7.3 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P 100#
| 10.3 | 5.0 | 2.3 | 18.8 | 22.8 | 13.0 | 14.8 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
| 2.4 | -18.0 | -18.8 | 4.9 | 55.9 | 18.2 | 43.3 |
|
S&P 100
| 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 | -5.8 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
|
226.7 | 20,209.1 | 2,458.8 | -881.7 | -26.4 | -24.9 | -- | 7.0 |
| 1,023.2 | 63,631.2 | 8,446.3 | 2,595.8 | 21.8 | 33 | 38.9 | 7.9 | |
| 13.5 | 850.9 | 0.0 | -175.9 | -- | -106.8 | -- | 5.7 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 33.2 | 20,720.0 | 4,131.1 | 788.1 | 21.5 | 13.4 | 26.2 | 3.5 | |
| 12.4 | 2,151.8 | 549.1 | 17.9 | -6.3 | 1.4 | 123.8 | 1.7 | |
| 17.4 | 2,261.9 | 120.3 | -57.5 | -108.2 | -9.9 | -- | 4.1 | |
| 11.7 | 828.1 | 366.5 | 9.3 | 8.3 | 3.4 | 83.6 | 3.1 | |
| 13.4 | 834.1 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 21.8 | |
| 26.1 | 2,927.9 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 5.0 |
Shareholding Pattern
View DetailsAbout BeiGene (BGNE)
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of... Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. Read more
-
Co-Founder, Executive Chairman & CEO
Mr. John V. Oyler
-
Co-Founder, Executive Chairman & CEO
Mr. John V. Oyler
-
Headquarters
Camana Bay
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for BeiGene (BGNE)
What is the current share price of BeiGene Ltd (BGNE) Today?
The share price of BeiGene Ltd (BGNE) is $226.71 (NASDAQ) as of 29-Jan-2025 09:30 EDT. BeiGene Ltd (BGNE) has given a return of 2.11% in the last 3 years.
What is the current PB & PE ratio of BeiGene Ltd (BGNE)?
Since, TTM earnings of BeiGene Ltd (BGNE) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
What is the 52 Week High and Low of BeiGene Ltd (BGNE)?
The 52-week high and low of BeiGene Ltd (BGNE) are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of BeiGene Ltd (BGNE)?
BeiGene Ltd (BGNE) has a market capitalisation of $ 20,209 Mln as on 29-Jan-2025. As per SEBI classification, it is a Large Cap company.
Should I invest in BeiGene Ltd (BGNE)?
Before investing in BeiGene Ltd (BGNE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.